Can you specify what you are measuring and provide references, as many/most of the useful measures of quality do not place the US near the top?
http://www.commonwealthfund.org/usr...hltsysdata2006_chartbook_972.pdf?section=4039
Disease-specific comparisons can be useful. Some conditions are sensitive to changes in health services (such as obstetrical care), while some are less-so (such as low-birth-weight which is more sensitive to social and other issues). Cancer outcomes are fairly heterogeneous when it comes to sensitivity to health care. Caution should be used in interpretation. For example, a large portion of the cancers (breast, prostate, melanoma) can show a lead-time and length bias due to screening programs. This can have the effect of artificially improving survival rates without changing outcomes.
The presence of pharmaceutical companies does not necessarily mean that new and useful drugs are developed. In "The Truth About the Drug Companies" by Marcia Angell (former editor of NEJM), a closer look at the source of innovative drugs shows that they are just as likely (if not more so) to come from government, non-profit or non-US-based pharmaceutical companies, as they are to come from US-based pharmaceutical companies. Most of the R & D goes to "me-too" drugs and patent-extending research instead.
The US is in the bottom half of the pack when it comes to doctors per capita.
You are grossly over-estimating the impact of new technologies on health care. The assumption that more medical care necessarily means better health is unsupported.
I'm not saying that any particular system is good or bad. It just makes sense to me to try to use accurate and relevant information.
Linda